OBJECTIVES: Although the incidence of pediatric inflammatory bowel disease (IBD) continues to rise in Northern France, the risks of death and cancer in this population have not been characterized. METHODS: All patients <17 years, recorded in EPIMAD registry, and diagnosed between 1988 and 2004 with Crohn's disease (CD) or ulcerative colitis (UC) were included. The observed incidences of death and cancer were compared with those expected in the regional general population obtained by French Statistical Institute (INSEE) and the cancer Registry from Lille. Comparisons were performed using Fisher's exact test and were expressed using the standardized mortality ratios (SMRs) and standardized incidence ratios. RESULTS: A total of 698 patients (538 with CD and 160 with UC) were identified; 360 (52%) were men, the median age at IBD diagnosis was 14 years (12-16) and the median follow-up time was 11.5 years (7-15). During follow-up, the mortality rate was 0.84% (6/698) and did not differ from that in the reference population (SMR=1.4 (0.5-3.0); P=0.27). After a median follow-up of 15 years (10-17), 1.3% of patients (9/698) had a cancer: colon (n=2), biliary tract (cholangiocarcinoma; n=1), uterine cervix (n=1), prepuce (n=1), skin (basal cell carcinoma (n=2), hematological (acute leukemia; n=1), and small bowel carcinoid (n=1). There was a significantly increased risk of cancer regardless of gender and age (standardized incidence ratio=3.0 (1.3-5.9); P<0.02). Four out of nine patients who developed a cancer had received immunosuppressants or anti-tumor necrosis factor-α therapy (including combination therapy in three patients). CONCLUSIONS: In this large pediatric population-based IBD cohort, mortality did not differ from that of the general population but there was a significant threefold increased risk of neoplasia.
OBJECTIVES: Although the incidence of pediatric inflammatory bowel disease (IBD) continues to rise in Northern France, the risks of death and cancer in this population have not been characterized. METHODS: All patients <17 years, recorded in EPIMAD registry, and diagnosed between 1988 and 2004 with Crohn's disease (CD) or ulcerative colitis (UC) were included. The observed incidences of death and cancer were compared with those expected in the regional general population obtained by French Statistical Institute (INSEE) and the cancer Registry from Lille. Comparisons were performed using Fisher's exact test and were expressed using the standardized mortality ratios (SMRs) and standardized incidence ratios. RESULTS: A total of 698 patients (538 with CD and 160 with UC) were identified; 360 (52%) were men, the median age at IBD diagnosis was 14 years (12-16) and the median follow-up time was 11.5 years (7-15). During follow-up, the mortality rate was 0.84% (6/698) and did not differ from that in the reference population (SMR=1.4 (0.5-3.0); P=0.27). After a median follow-up of 15 years (10-17), 1.3% of patients (9/698) had a cancer: colon (n=2), biliary tract (cholangiocarcinoma; n=1), uterine cervix (n=1), prepuce (n=1), skin (basal cell carcinoma (n=2), hematological (acute leukemia; n=1), and small bowel carcinoid (n=1). There was a significantly increased risk of cancer regardless of gender and age (standardized incidence ratio=3.0 (1.3-5.9); P<0.02). Four out of nine patients who developed a cancer had received immunosuppressants or anti-tumor necrosis factor-α therapy (including combination therapy in three patients). CONCLUSIONS: In this large pediatric population-based IBD cohort, mortality did not differ from that of the general population but there was a significant threefold increased risk of neoplasia.
Authors: Hari K Somineni; Suresh Venkateswaran; Varun Kilaru; Urko M Marigorta; Angela Mo; David T Okou; Richard Kellermayer; Kajari Mondal; Dawayland Cobb; Thomas D Walters; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Joel R Rosh; David R Mack; Melvin B Heyman; Susan S Baker; Michael C Stephens; Robert N Baldassano; James F Markowitz; Marla C Dubinsky; Judy Cho; Jeffrey S Hyams; Lee A Denson; Greg Gibson; David J Cutler; Karen N Conneely; Alicia K Smith; Subra Kugathasan Journal: Gastroenterology Date: 2019-02-16 Impact factor: 22.682
Authors: Nicholas Y Tan; Shounak Majumder; Meera Sridharan; Sarah E Kerr; Rondell P Graham; Karthik Ravi Journal: Am J Gastroenterol Date: 2017-03 Impact factor: 10.864
Authors: Antony Cougnoux; Miyad Movassaghi; Jaqueline A Picache; James R Iben; Fatemeh Navid; Alexander Salman; Kyle Martin; Nicole Y Farhat; Celine Cluzeau; Wei-Chia Tseng; Kathryn Burkert; Caitlin Sojka; Christopher A Wassif; Niamh X Cawley; Richard Bonnet; Forbes D Porter Journal: Dig Dis Sci Date: 2018-01-22 Impact factor: 3.199
Authors: Murat Cakir; Fatih Unal; Gonul Dinler; Masallah Baran; Hasan Ali Yuksekkaya; Gokhan Tumgor; Erhun Kasirga; Ayhan Gazi Kalayci; Sema Aydogdu Journal: World J Pediatr Date: 2015-10-11 Impact factor: 2.764
Authors: Marco Gasparetto; Graziella Guariso; Laura Visona' Dalla Pozza; Alexander Ross; Robert Heuschkel; Matthias Zilbauer Journal: BMC Gastroenterol Date: 2016-03-15 Impact factor: 3.067